ARDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 28 cases where ARDX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARDX's RSI Oscillator exited the oversold zone, 22 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 59 cases where ARDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +4.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in 224 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARDX as a result. In 65 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for ARDX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ARDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.544) is normal, around the industry mean (2.973). P/E Ratio (-13.913) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (50.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.846) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Oscillator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 68 cases where MLTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on MLTX as a result. In 80 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 43 of 53 cases over the following month. The odds of a continued upward trend are 81%.
The 50-day moving average for MLTX moved below the 200-day moving average on September 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
MLTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MLTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.453) is normal, around the industry mean (2.973). P/E Ratio (-3.214) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ARDX | MLTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 80 | 95 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 84 | 65 | |
P/E GROWTH RATING 1..100 | 14 | 14 | |
SEASONALITY SCORE 1..100 | n/a | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MLTX's Valuation (37) in the null industry is somewhat better than the same rating for ARDX (97) in the Biotechnology industry. This means that MLTX’s stock grew somewhat faster than ARDX’s over the last 12 months.
ARDX's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as MLTX (95) in the null industry. This means that ARDX’s stock grew similarly to MLTX’s over the last 12 months.
ARDX's SMR Rating (97) in the Biotechnology industry is in the same range as MLTX (98) in the null industry. This means that ARDX’s stock grew similarly to MLTX’s over the last 12 months.
MLTX's Price Growth Rating (65) in the null industry is in the same range as ARDX (84) in the Biotechnology industry. This means that MLTX’s stock grew similarly to ARDX’s over the last 12 months.
MLTX's P/E Growth Rating (14) in the null industry is in the same range as ARDX (14) in the Biotechnology industry. This means that MLTX’s stock grew similarly to ARDX’s over the last 12 months.
| ARDX | MLTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 74% |
| MACD ODDS (%) | N/A | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 74% |
| Advances ODDS (%) | 8 days ago 85% | 1 day ago 84% |
| Declines ODDS (%) | 10 days ago 80% | 9 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARDX’s FA Score shows that 1 FA rating(s) are green while MLTX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARDX’s TA Score shows that 4 TA indicator(s) are bullish while MLTX’s TA Score has 5 bullish TA indicator(s).
ARDX (@Biotechnology) experienced а -2.14% price change this week, while MLTX (@Biotechnology) price change was +20.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
ARDX is expected to report earnings on Nov 03, 2026.
MLTX is expected to report earnings on Nov 04, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To ARDX | 1D Price Change % | ||
|---|---|---|---|---|
| ARDX | 100% | +2.24% | ||
| VCYT - ARDX | 45% Loosely correlated | -0.39% | ||
| IMNM - ARDX | 39% Loosely correlated | +1.44% | ||
| CABA - ARDX | 39% Loosely correlated | -1.30% | ||
| MLTX - ARDX | 36% Loosely correlated | +15.87% | ||
| ELVN - ARDX | 35% Loosely correlated | +0.26% | ||
More | ||||